To read the full story, subscribe or sign in.

EMA validates two filings for Daiichi-Astrazeneca’s ADC

March 5, 2024

The EMA validated two marketing approval applications of Daiichi Sankyo Co. Ltd. and Astrazeneca plc’s antibody-drug conjugate (ADC) datopotamab deruxtecan (dato-dxd) on Mar. 4, for two types of lung and breast cancer.

BioWorld Asia Regulatory Cancer Oncology Antibody-drug conjugate Europe Japan BLA EMA FDA Phase III

Today's news in brief

BioWorld

BioWorld briefs for Nov. 21, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 21, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

Illustration of Microglia cells (red) in Alzheimer´s disease

Less microglia activity may improve APOE4’s effect in Alzheimer’s

BioWorld

Reducing microglial activity in the presence of apolipoprotein E4 (APOE4) has uncovered a mechanism associated with the deposition of misfolded amyloid and tau in...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

EMA validates two filings for Daiichi-Astrazeneca’s ADC